Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.
Zeigler Issues A Voluntary Recall on Pelleted and Crumbled Shrimp Feeds
FOR IMMEDIATE RELEASE — Gardners, PA — May 31, 2007 — In cooperation with the U. S. Food and Drug Administration, Zeigler Bros., Inc. is issuing a voluntary nationwide recall of its pelleted and crumbled shrimp feeds. Zeigler is recommending to customers to immediately stop feeding its pelleted and crumbled shrimp feed products. We are in the process of providing the entire shrimp feed product list on our website at www.zeiglerfeed.com.
The recalled products all include the feed ingredient "AquaBond", which has been found to contain the chemical melamine and related compounds. AquaBond is a binding agent purchased in the United States by Zeigler and used in its production of pelleted and crumbled shrimp feeds. It is used in a much lower concentration than similar ingredients used in the recent U. S. pet food recall.
No other Zeigler products are involved in this voluntary recall. Only Zeigler pelleted and crumbled shrimp feeds are formulated with AquaBond. Zeigler extruded shrimp feeds and shrimp larval feeds do not contain AquaBond and are not included in the recall.
Zeigler is working closely with the FDA and with Uniscope, Zeigler's supplier for AquaBond, to provide timely product information and immediate recall instructions to its customers to assure product safety. Zeigler is not aware of any instances of ill health effects in shrimp fed with Zeigler pelleted and crumbled shrimp feeds.
The FDA has issued a press release, dated May 30, 2007, indicating that feeds made with these binding agents are "very unlikely" to pose a human health risk. Details from the full FDA press release can be found at www.fda.gov/bbs/topics/NEWS/2007/NEW01643.html. FDA has also issued a safety/risk assessment on melamine and analogues at www.cfsan.fda.gov/~dms/melamra.htm.
Questions can be directed to Zeigler at 800-841-6800 or email@example.com.